How the Pivotal Trial for LivaNova’s OSA Neurostimulator Is Different from the Rest
When testing the aura6000 implant, LivaNova didn’t exclude patients who have historically been seen as poor candidates.
When testing the aura6000 implant, LivaNova didn’t exclude patients who have historically been seen as poor candidates.
The company reported a 43% increase in annual revenue for 2023, driven in part by greater adoption of its oral appliance therapy for obstructive sleep apnea.
Data submitted to the FDA from 73 severe OSA patients showed that 80% of patients experienced an improvement of at least one classification or at least a 50% improvement in the AHI.
ProSomnus announced plans to design a head-to-head clinical trial comparing its precision oral appliance therapy and hypoglossal nerve stimulation in treating patients with severe OSA.
Read MoreThe study also found the device to be more effective in mild to moderate and severe OSA patients compared to traditional oral appliance therapy.
Read MoreIt is hard to perform jaw advancement surgery without compromising on patients’ facial aesthetics. A pilot study of a new technique cured several people’s sleep apnea—all while maintaining their looks.
Read MoreA sleep physician reviews limitations of the apnea-hypopnea index and considers inclusion of additional variables to develop measures of OSA severity that may be more useful.
Read MoreA dental sleep medicine practitioner shares 5 years of data that show moderate and severe OSA patients can achieve successful outcomes with MADs. He calls for greater awareness of oral appliance utility.
Read More